Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis

Mevius, Antje; Karl, Florian; Wacker, Margarethe; Welte, R; Krenzer, Stefanie; Link, Theresa; Maywald, Ulf; Wilke, Thomas

doi:10.1007/s00432-022-04183-y

Cited by 4 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reference number is linked to information on the Anatomical Therapeutic Chemical classification code (ATC), 22 the defined daily dose, the packaging size, the strength and the formulation of the drug. 16-19 …”

Section: Methodsmentioning

confidence: 99%

Epidemiology, real-world treatment and mortality of patients with status epilepticus in Germany: insights from a large healthcare database

Mevius

Joeres

Gille

et al. 2023

Brain Communications

Self Cite

View full text Add to dashboard Cite

Status epilepticus (SE) is a life-threatening emergency and to date, few studies have reported on its long-term treatment and outcomes. This study aimed to estimate the incidence, the treatment and outcomes, the healthcare resource utilization and the costs of SE in Germany. Data from 2015 to 2019 were obtained from German claims (AOK PLUS) Patients with ≥1 SE event and no event in the preceding 12 months (baseline) were included. A subgroup of patients with epilepsy diagnosis during baseline was also analyzed. Of the 2,782 SE patients (mean age=64.3 years; 52.3% female), 1,585 (57.0%) were previously diagnosed with epilepsy. The age- and sex standardized incidence was 25.5 cases/100,000 persons in 2019. Mortality rate after 12 months was 39.8% overall (19.4% and 28.2% after 30 and 90 days respectively), and 30.4% in the epilepsy patient subgroup. Factors associated with higher mortality were age, comorbidity status, presence of brain tumors and an acute stroke. An epilepsy-related hospitalization at onset of or 7 days prior to the SE event as well as prescription of antiseizure medication (ASM) during baseline were associated with a better survival rate. Overall, 71.6% of patients (85.6% in epilepsy subgroup) were prescribed with outpatient ASM and/or rescue medication within 12 months. All patients sustained on average 1.3 SE-related hospitalizations (20.5% had >1) during a mean follow-up period of 545.2 days (median 514 days); total direct costs including inpatient and outpatient SE-treatment were 10,826€ and 7,701€ per patient-year overall and for epilepsy patient subgroup respectively. The majority of SE patients received an outpatient treatment in line with epilepsy guidelines, patients previously diagnosed with epilepsy have a higher likelihood to receive it. The mortality in the affected patient population is high; risk factors were older age, higher comorbidity burden, the presence of brain tumors or an acute stroke.

show abstract

Section: Methodsmentioning

confidence: 99%

Epidemiology, real-world treatment and mortality of patients with status epilepticus in Germany: insights from a large healthcare database

Mevius

Joeres

Gille

et al. 2023

Brain Communications

Self Cite

View full text Add to dashboard Cite

show abstract

“…репарации -несоответствие нуклеотидов Proficient Mismatch Repair (pMMR)/Microsatellite Stable (MSS), проведенное в Великобритании в 2022 г., в Германиив 2020 г. и в США -в 2019 г. [5][6][7][8][9][10]. Подобная ситуация обусловлена отсутствием инновационных методов в лечении РТМ в течение последних 15 лет [11].…”

Section: оригинальные исследованияunclassified

Organization clinical decision-making programs in the local practice of the region: problematic issues that determine the choice of therapy in the progression of endometrial cancer

Goryainova,

Leonov,

Murashko

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. For the treatment of uterine body cancer (UBC), modern oncologists have at their disposal clinical recommendations of scientific communities, the set of drug options in which is represented by a limited range of drugs that have not been studied enough (phase II studies, no more than 52 patients in each). There is an obvious lack of information about clinical routine data systematization algorithms that describe the molecular biological features of the tumor, its prevalence, patient characteristics, existing treatment models, and form a decision-making program when planning the treatment of UBC patients.Aim. Тo develop an algorithm for routing patients with UBC on the territory of the Krasnodar Region in the existing conditions for organizing medical care and human resources.Materials and methods. Local observational retrospective study. Sources – medical records. The data were collected by the co-authors of the article in the course of daily clinical activities. Information from the medical records of 72 patients with endometrial cancer who were referred for microsatellite instability (MSI) testing at the Oncological Dispensary of Krasnodar from 01/01/2021 to 11/16/2022 was analyzed to determine the possibility of receiving immuno/immuno-targeted therapy in the second and subsequent lines medicinal treatment.Results. In the Krasnodar Oncological Dispensary all the therapy options specified in the clinical guidelines were used. One line of systemic therapy for a common disease was received by 61 patients out of 72, only 41 patients received the second line, and only 19 patients received the third line. Five patients received the immunotargeted combination in the second line and 3 in the third. One patient received immunotherapy with pembrolizumab in the third line. One patient received immunotherapy with pembrolizumab in the third line. An analysis of the factors influencing the possibility of receiving this therapy showed the importance of timely genetic testing of MSI, as well as related organizational issues, such as the ability to quickly receive treatment and ensure appropriate follow-up of patients.Conclusions. Based on the study, low awareness of clinicians about the possibility and necessity of early testing for the presence of MSI in an endometrial tumor was revealed. The organization of delivery of material from clinics that have a territorial remoteness, insufficient access to patient consultations by related specialists, and low patient compliance limit the introduction of modern methods of therapy for UBC patients. Establishing a system of close professional interaction between physicians will contribute to a wider introduction of new methods of diagnosis and treatment of UBC patients.

show abstract

Real-world dostarlimab use in advanced/recurrent endometrial cancer in France

Rodrigues,

Eberst,

Follana

et al. 2023

Bulletin du Cancer

View full text Add to dashboard Cite

Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis

Cited by 4 publications

References 18 publications

Epidemiology, real-world treatment and mortality of patients with status epilepticus in Germany: insights from a large healthcare database

Epidemiology, real-world treatment and mortality of patients with status epilepticus in Germany: insights from a large healthcare database

Organization clinical decision-making programs in the local practice of the region: problematic issues that determine the choice of therapy in the progression of endometrial cancer

Real-world dostarlimab use in advanced/recurrent endometrial cancer in France

Contact Info

Product

Resources

About